Recent studies have demonstrated that chemotherapy was more effective than EGFR inhibitors, gefitinib or erlotinib, to prolong the progression-free survival and overall survival of patients with NSCLC who exhibited wild-type EGFR.2, 3, 4 Thus, improving effectiveness of chemotherapy is also of great significance for the particular NSCLC patients. This evidence concerns the gene EGFR and non-small cell lung carcinoma.